Morning Overview on MSN

The FDA approved a cell therapy to curb a deadly complication of stem-cell transplants

Children who survive a stem-cell transplant only to watch their own donor cells attack their organs now have a ...
Benzinga.com

Mesoblast Says Most Children Survive After Early Use Of FDA-Approved Cell Therapy For Organ Transplant Related Complication

Mesoblast Limited (NASDAQ: MESO) on Monday provided an update on the use of Ryoncil (remestemcel-L-rknd) since commercially available in March 2025 for the approved label in children 2 months and ...
Seeking Alpha

Mesoblast gains as FDA clears study to test Ryoncil in Duchenne

Mesoblast (MESO) added ~6% in the premarket on Wednesday after the FDA cleared its Investigational New Drug application that sought approval to conduct a study to test its cell therapy, Ryoncil, in ...

Mesoblast Showcases Profitable Ryoncil Launch and Expanding Cell Therapy Pipeline in June 2026 CEO Presentation

Detailed price information for Mesoblast Ltd ADR (MESO-Q) from The Globe and Mail including charting and trades.
Stockhead

Prenzler’s three ASX stem-cell stocks to watch as sector matures

Prenzler sees upside in stem cell sector with investment case being driven by several positive tailwinds and names three ASX stocks to watch.